Parkman Healthcare Partners LLC Lowers Stock Holdings in Keros Therapeutics, Inc. $KROS

Key Points

• Parkman Healthcare Partners LLC reduced its stake in Keros Therapeutics by 30.8%, owning 217,753 shares valued at approximately $2.22 million after selling 96,788 shares in the first quarter.
• Several hedge funds increased their positions significantly, with ADAR1 Capital Management growing its stake by 6,294.5% during the same period, now holding 1,486,461 shares worth $15.15 million.
• Bank of America downgraded Keros Therapeutics from a "buy" to a "neutral" rating, reducing its price target from $32.00 to $18.00, reflecting increased caution among analysts.

Parkman Healthcare Partners LLC trimmed its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 30.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 217,753 shares of the company's stock after selling 96,788 shares during the quarter. Parkman Healthcare Partners LLC owned 0.54% of Keros Therapeutics worth $2,219,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. ADAR1 Capital Management LLC grew its position in shares of Keros Therapeutics by 6,294.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,486,461 shares of the company's stock worth $15,147,000 after buying an additional 1,463,215 shares in the last quarter. Federated Hermes Inc. grew its position in shares of Keros Therapeutics by 882.3% during the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company's stock worth $12,474,000 after buying an additional 1,099,519 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Keros Therapeutics by 31.1% during the first quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company's stock worth $26,151,000 after buying an additional 609,212 shares in the last quarter. DRW Securities LLC acquired a new position in shares of Keros Therapeutics during the first quarter worth about $4,737,000. Finally, Millennium Management LLC grew its position in shares of Keros Therapeutics by 53.3% during the fourth quarter. Millennium Management LLC now owns 878,159 shares of the company's stock worth $13,901,000 after buying an additional 305,169 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on KROS shares. Bank of America downgraded Keros Therapeutics from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $32.00 to $18.00 in a research report on Tuesday, June 10th. Wedbush reissued a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a research report on Friday, May 30th. Scotiabank cut their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 12th. Finally, HC Wainwright cut their target price on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Seven analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $30.00.

Keros Therapeutics Trading Up 0.3%

Shares of NASDAQ KROS opened at $15.59 on Friday. Keros Therapeutics, Inc. has a twelve month low of $9.12 and a twelve month high of $72.37. The stock has a 50 day moving average of $14.39 and a two-hundred day moving average of $13.31. The stock has a market cap of $633.27 million, a P/E ratio of 50.29, a P/E/G ratio of 2.00 and a beta of 1.06.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, beating analysts' consensus estimates of ($1.14) by $0.38. The company had revenue of $0.02 million during the quarter, compared to analysts' expectations of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The firm's revenue for the quarter was up 49002.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.25) earnings per share. As a group, research analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.